...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Clovis' Rubracra
6
Oct 03, 2018 01:02PM
6
Oct 05, 2018 03:18AM

I agree that “late to the party” does not likely apply regarding PARP inhibitors, Don included PARP inhibitors in the list of drug classes that ZEN 3694 works synergistically with. I believe it was within the first 10 slides when he mentions the synergistic list. 

7
Oct 05, 2018 12:12PM
Share
New Message
Please login to post a reply